


IFW



Please Direct All Correspondence to Customer Number **20995**

**TRANSMITTAL LETTER**  
**INFORMATION DISCLOSURE STATEMENT**

Applicant : Stegmann, et al.  
App. No : 10/649,480  
Filed : August 27, 2003  
For : METHOD OF PRODUCING  
BIOLOGICALLY ACTIVE FIBROBLAST  
GROWTH FACTOR AND ITS USE IN  
PROMOTING ANGIOGENESIS  
Examiner : Li, Bao Q.  
Art Unit : 1648

**CERTIFICATE OF MAILING**

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

July 11, 2005

(Date)

Che S. Chereskin

Che Swyden Chereskin, Ph.D., Reg. No. 41,466

**Mail Stop Amendment**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application are:

- (X) An Information Disclosure Statement and PTO/SB/08 equivalent listing and enclosing 5 references for consideration
- (X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment, to Account No. 11-1410.
- (X) Return prepaid postcard.

Che S. Chereskin


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404



INFORMATION DISCLOSURE STATEMENT

Applicant : Stegmann et al.  
 App. No : 10/649,480  
 Filed : August 27, 2003  
 For : METHOD OF PRODUCING BIOLOGICALLY  
 ACTIVE FIBROBLAST GROWTH FACTOR  
 AND ITS USE IN PROMOTING  
 ANGIOGENESIS  
 Examiner : Li, Bao Q.  
 Art Unit : 1648

Mail Stop Amendment  
 Commissioner for Patents  
 P.O. Box 1450  
 Alexandria, VA 22313-1450

Dear Sir:

Enclosed for filing in the above-identified application is a PTO/SB/08 Equivalent listing 5 references to be considered by the Examiner. Also enclosed are 5 foreign patent references and/or non-patent literature as listed on the Information Disclosure Statement.

This Information Disclosure Statement is being filed before the mailing date of a final action and before the mailing date of a Notice of Allowance.

CERTIFICATION UNDER 37 C.F.R. § 1.97(e)(1)

I hereby certify that each item of information contained in this Statement was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.

Thus, no fee is required as set forth in 37 C.F.R. § 1.97(c).

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

July 14, 2005

By:

Che S. Chereskin


Che Swyden Chereskin, Ph.D.

Registration No. 41,466

Agent of Record

Customer No. 20,995

(949) 760-0404



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>	Application No.	10/649,480
	Filing Date	August 27, 2003
	First Named Inventor	Stegmann, et al.
	Art Unit	1648
(Multiple sheets used when necessary)	Examiner	Li, Bao Q.
SHEET 1 OF 1	Attorney Docket No.	CVBIO.008CP1

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number - Kind Code (if known) Example: 1,234,567 B1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind Code Example: JP 1234567 A1	Publication Date MM-DD-YYYY	Name of Patentee or Applicant	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T <sup>1</sup>
		SU 1 089 119	04/30/84	AS UKR Molecul Biol		Abstract

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>1</sup>
		Sorochinskaya, et al. "Study of Beta Lactamase Tem1 Synthesis in Various <i>Escherichia coli</i> Strains Infected by the Phage Lambda-BLA with Amber Mutations in Different Regulatory Genes," <i>Biopolimery I Kletka</i> , Vol. 7, No. 1, pp 101-107, 1991 (abstract)	
		Watanabe, et al. "Molecular Characterization of Recombinant Human Acidic Fibroblast Growth Factor Produced in <i>E. coli</i> : Comparative Studies with Human Basic Fibroblast Growth Factor," <i>Molecular Endocrinology</i> , Vol. 4, No. 6, pp. 869-879, 1990.	
		Zazo, et al. "High-Level Synthesis in <i>Escherichia coli</i> of Shortened and Full-Length Human Acidic Fibroblast Growth Factor and Purification in a Form Stable in Aqueous Solutions," <i>Gene</i> , Vol. 113, No. 2, pp. 231-238, January, 1992.	
		Supplementary European Search Report completed May 31, 2005 and issued to a related foreign application.	

1801771  
070605

Examiner Signature	Date Considered
<b>*Examiner:</b> Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

T<sup>1</sup> - Place a check mark in this area when an English language Translation is attached.